Manual Washington de Dermatología®

1 5 1

Capítulo 8 • Lesiones cutáneas malignas

10. Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013;339(6122):959–961. 11. Eggermont A. Randomized trials in melanoma: an update. Surg Oncol Clin N Am 2006;15(2):439–451. 12. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015;372(1):30–39. 13. Wolchok J, Kluger H, Callahan M, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369(2):122–133. 14. Jawed S, Myskowski P, Horwitz S, et al. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol 2014;70(2):205.e1205.e16. 15. Siegel RS, Pandolfino T, Guitart J, et al. Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol 2000;18(15):2908–2925. 16. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007;110(6):1713–1722.

17. Jawed S, Myskowski P, Horwitz S, et al. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions. J Am Acad Dermatol 2014;70(2):223.e1223.e17. AMPLE